MediciNova Secures Patent for MN-166/Anti-PD-1 Glioblastoma Therapy, Expires 2042
MNOV•MediciNova received a USPTO Notice of Allowance on June 8 for a patent covering use of ibudilast (MN-166) combined with anti-PD-1 antibodies in glioblastoma, with claims spanning dosing regimens, administration routes and therapy duration. The patent, expiring no earlier than September 2042, bolsters the company’s oncology IP estate.
1. Patent Allowance Granted for Glioblastoma Therapy
On June 8, 2026, MediciNova received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent covering the use of ibudilast (MN-166) in combination with anti-PD-1 antibodies for glioblastoma treatment.
2. Broad Claims and Expiration Details
The allowed claims encompass multiple treatment parameters including dosing regimens, administration routes and therapy duration; the patent is set to expire no earlier than September 2042, extending MediciNova’s IP protection.
3. Strategic Impact on MediciNova
This patent strengthens the company’s oncology intellectual property estate and underpins its combination therapy development strategy for aggressive malignancies, potentially enhancing investor outlook and partnership opportunities.
